Engineered antibody Fc variants with enhanced effector function

Proceedings of the National Academy of Sciences of the United States of America
Greg A LazarBassil I Dahiyat

Abstract

Antibody-dependent cell-mediated cytotoxicity, a key effector function for the clinical efficacy of monoclonal antibodies, is mediated primarily through a set of closely related Fcgamma receptors with both activating and inhibitory activities. By using computational design algorithms and high-throughput screening, we have engineered a series of Fc variants with optimized Fcgamma receptor affinity and specificity. The designed variants display >2 orders of magnitude enhancement of in vitro effector function, enable efficacy against cells expressing low levels of target antigen, and result in increased cytotoxicity in an in vivo preclinical model. Our engineered Fc regions offer a means for improving the next generation of therapeutic antibodies and have the potential to broaden the diversity of antigens that can be targeted for antibody-based tumor therapy.

References

May 1, 1996·Protein Science : a Publication of the Protein Society·B I Dahiyat, S L Mayo
Jan 1, 1996·Annual Review of Cell and Developmental Biology·M Raghavan, P J Bjorkman
Mar 1, 1997·Analytical Biochemistry·P R Edwards, R J Leatherbarrow
Jan 8, 2000·Seminars in Immunology·S Amigorena, C Bonnerot
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Feb 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E E IdusogieM G Mulkerrin
Jul 13, 2000·Protein Science : a Publication of the Protein Society·K RahaJ R Desjarlais
Sep 15, 2000·Journal of Immunological Methods·F G Leppers-van de StraatJ G van de Winkel
Jun 9, 2001·Journal of Molecular Biology·P SondermannU Jacob
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Apr 17, 2002·Molecular Immunology·Sergei Radaev, Peter Sun
Apr 27, 2002·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Linda K ErnstPenelope A Morel
May 15, 2002·Immunology Letters·Roy Jefferis, John Lund
Jun 19, 2002·The Journal of Experimental Medicine·Alexis M Kalergis, Jeffrey V Ravetch
Jul 3, 2002·The Journal of Clinical Investigation·Khadija RafiqRaphael Clynes
Sep 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·Madhav V DhodapkarKara Olson
Mar 14, 2003·Drug Discovery Today·Shannon A MarshallJohn R Desjarlais
Aug 5, 2003·The Oncologist·Jeffrey S RossKenneth J Bloom
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy
Apr 15, 2004·Immunology Letters·Joël F G Cohen-SolalCatherine Sautès-Fridman
Jul 1, 2004·Blood·Guillaume CartronPhilippe Solal-Celigny
Apr 13, 2005·Proceedings of the National Academy of Sciences of the United States of America·Veronika GrohThomas Spies
May 7, 2005·Nature Biotechnology·Louis M Weiner, Paul Carter

❮ Previous
Next ❯

Citations

May 29, 2010·Archivum Immunologiae Et Therapiae Experimentalis·Stefan LohseMichael Dechant
Oct 23, 2008·Cancer Immunology, Immunotherapy : CII·Panagiotis KaragiannisSophia N Karagiannis
Aug 7, 2009·Cancer Immunology, Immunotherapy : CII·Pina M CardarelliDavid J King
Aug 26, 2011·Journal of Molecular Modeling·Pawan Kumar RaghavGurudutta U Gangenahalli
Feb 25, 2009·Clinical and Experimental Medicine·Michela Cesco-GaspereHans J Stauss
Nov 24, 2011·Current Hematologic Malignancy Reports·Joseph G Jurcic
Jan 19, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Philippe Fournier, Volker Schirrmacher
Aug 14, 2009·Expert Reviews in Molecular Medicine·Lisa C WillcocksMenna R Clatworthy
Aug 10, 2010·Acta Pharmacologica Sinica·Jing Li, Zhenping Zhu
Feb 6, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Benjamin Joachim SchmiedelHelmut Rainer Salih
Dec 11, 2007·Nature Biotechnology·Wayne A Marasco, Jianhua Sui
Aug 25, 2006·Nature Reviews. Cancer·Kohzoh Imai, Akinori Takaoka
Mar 31, 2012·Nature Reviews. Drug Discovery·P Mark Hogarth, Geoffrey A Pietersz
Feb 2, 2011·Nature Reviews. Drug Discovery·Xu-Rong JiangMark Schenerman
Apr 20, 2006·Nature Reviews. Immunology·Paul J Carter
Dec 8, 2007·Nature Reviews. Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Apr 24, 2010·Nature Reviews. Immunology·Louis M WeinerShangzi Wang
Oct 10, 2009·Proceedings of the National Academy of Sciences of the United States of America·Randall J BrezskiRobert E Jordan
Jan 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Sang Taek JungGeorge Georgiou
Apr 5, 2012·Proceedings of the National Academy of Sciences of the United States of America·Patrick SmithJeffrey V Ravetch
Jun 23, 2012·Proceedings of the National Academy of Sciences of the United States of America·Fubin Li, Jeffrey V Ravetch
Oct 27, 2012·Proceedings of the National Academy of Sciences of the United States of America·Brian MoldtDennis R Burton
Dec 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Shazad Q AshrafWalter F Bodmer
May 3, 2011·The Journal of Biological Chemistry·Achim BoltzBjoern Hock
Feb 2, 2012·The Journal of Biological Chemistry·Javier Chaparro-RiggersArvind Rajpal
Dec 30, 2008·The Journal of Biological Chemistry·Agoston JergaCharles O Rock
Aug 28, 2013·The Journal of Experimental Medicine·Jeong M Kim, Avi Ashkenazi
Feb 1, 2011·Journal of Biochemistry·Hiroaki NagashimaYasuhiko Masuho
Jul 4, 2009·Protein Engineering, Design & Selection : PEDS·Almer M Van der SlootFrancois Stricher
May 21, 2011·Protein Engineering, Design & Selection : PEDS·Ross StewartJohn Lund
Jul 6, 2012·Protein Engineering, Design & Selection : PEDS·Jonas V Schaefer, Andreas Plückthun
Oct 30, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Stephane BonettoJohn Lund
Oct 13, 2012·Anti-cancer Drugs·Jay J ListinskyCatherine M Listinsky
Jun 10, 2008·The Cancer Journal·LiNa LooGregory P Adams
Mar 28, 2009·Journal of the Royal Society, Interface·María Suárez, Alfonso Jaramillo
Mar 25, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jonathan P ButcharSusheela Tridandapani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.